Published in TB and Outbreaks Week, March 20th, 2001
The product, known as LAPDAP, combines two existing anti-malarial compounds (chlorproguanil and dapsone) and is a potential life-saving medicine, WHO said.
The agreement aims at developing the drug as an oral treatment for uncomplicated malaria, primarily for use in Sub-Saharan Africa. Clinical trials in the region have shown that LAPDAP is effective in treating uncomplicated malaria resistant to other standard therapies.
The drug will be made available at a preferential price for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week